Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia.
Results of the BMF study group trials ALL-REZ 83 and 85 for relapsed acute lymphoblastic leukemia (ALL) are presented. For children with late marrow relapse, remission rates of about 90% were seen in both studies. In children treated for early marrow relapse, the remission rate in study ALL-REZ 85 was superior (86% vs 62%). The probability of event-free survival for all patients and for those with early marrow relapse was also statistically significant (P less than 0.05). Children with T-cell ALL had an extremely unfavourable prognosis in both studies.
Henze
G
G
Kinderklinik, Freie Universität Berlin.
Fengler
R
R
Hartmann
R
R
Dopfer
R
R
Göbel
U
U
Graf
N
N
Jürgens
H
H
Niethammer
D
D
Ritter
J
J
Schellong
G
G
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000188:drug therapy* / Q000401:mortality; D016026:Bone Marrow Transplantation; D002648:Child; D003131:Combined Modality Therapy; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D011897:Random Allocation; D012008:Recurrence; D012074:Remission Induction; D013997:Time Factors